Skip to content Skip to footer
Subscribe Now
News

Hanx Biopharmaceuticals Reports the First Patient Dosing with HX044 in P-I Clinical Evaluation

Shots: Hanx Biopharmaceuticals has dosed the first patient with HX044 under its P-I clinical evaluation for treating solid tumors The dose escalation & expansion P-I/IIa (HX044-I-01) trial will assess safety, tolerability, PK profile & initial efficacy of HX044 for the treatment of advanced solid tumor malignancies HX044 is a first-in-class bispecific antibody and…
January 3, 2025

Read more

Key Biosimilars Events of September 2024
INSIGHTS+

Key Biosimilars Events of September 2024

Shots:       Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency        Biosimilars are expected to be a cost-effective alternative to the high-priced branded biologics, offering significant and much-needed cost savings to both payers and patients        The major highlights were the US FDA’s approval of Samsung Bioepis and…
October 3, 2024

Read more

News

The NMPA Clears Shanghai Henlius’ IND Application of HLX17 (Biosimilar, Keytuda) for Treating Solid Tumors

Shots:  The NMPA has cleared IND application of HLX17 to conduct its clinical study in comparison with Keytruda for treating melanoma, NSCLC, esophageal cancer, HNSCC, CRC, HCC, biliary tract cancer, TNBC, MSI-H/dMMR cancer & gastric cancer   HLX17 was assessed under pharmacologic comparative trial, preclinical pharmacology study as well as PK/PD & immunogenicity studies that showed similarity…
September 2, 2024

Read more

Viewpoints_Efrat Kaduri
VIEWPOINTS

Off the Shelf Platform: Efrat Kaduri from Pluri Inc. In a Riveting Conversation with PharmaShots

Shots:  Recently, Pluri launched its placental allogenic MAIT cell platform for immunotherapy treatment of solid tumors. Mucosal Associated Invariant T (MAIT) cells offer better advantages as compared to conventional T cells  Today, we have with us Efrat Kaduri shedding light on the potential of placental MAIT cells in treating solid tumors  While highlighting the intellectual…
July 10, 2024

Read more

VIEWPOINTS_Robert Connelly_2023
VIEWPOINTS

Robert Connelly shares the highlights of the post-merger between Elicio Therapeutics & Angion Biomedica Corp.

Shots:  Robert Connelly, CEO of Elicio Therapeutics, shared his views on the aftermath of the merger between Elicio Therapeutics & Angion Biomedica Corp. The strategic merger is instrumental to further advance Elicio’s product candidates with a focus on advancing its proprietary lymph node targeting Amphiphile (AMP) technology to develop immunotherapies  Robert recapitulates data presented at ASCO…
October 9, 2023

Read more

VIEWPOINTS_Matthew Robinson_2023
VIEWPOINTS

Matthew Robinson, CTO, Immunome Shares Insights on Strategic Collaboration with AbbVie to Identify Multiple Novel Oncology Targets

Shots: Matthew spoke about Immunome’s collaboration and option agreement with AbbVie for the discovery of up to 10 novel antibody-target pairs arising from three specified tumor types using Immunome’s Discovery Engine He also talked about how the partnership with AbbVie can support Immunome’s strategy to maximize the new drug discovery potential of its Discovery Engine…
May 8, 2023

Read more

Viewpoints_Garret Hampton
VIEWPOINTS

Garret Hampton, President, Clinical Sequencing & Oncology at Thermo Fisher Scientific Shares Insights from the Approval of the First NGS-Based Companion Diagnostic for HER2-Mutant NSCLC

Shots: Garret spoke about the approval of the first NGS-based companion diagnostic to aid in selecting NSCLC patients with HER2  activating mutations for treatment with ENHERTU Garret also talked about the Oncomine Dx Target Test and its availability for different targeted therapies in multiple geographies The interview highlights how Thermo Fisher is working to develop accessible CDx solutions…
October 25, 2022

Read more

Viewpoints_Carsten Linnemann
VIEWPOINTS

Carsten Linnemann, CEO at Neogene Therapeutics Shares Insights on the Approval of CTA for the P-I Trial of its TCR Therapy to Treat Solid Tumors

Carsten spoke about the approval of CTA by the Dutch regulatory authority for a P-I study evaluating its TCR therapy for the treatment of solid tumors Carsten also emphasized how NT-125 will be different from other TCR therapies The interview shows the advancement of Neogene’s pipeline developing transformative TCR therapies targeting neoantigens in solid cancers…
September 7, 2022

Read more

PharmaShots Interview SOTIO Richard Sachse Shares Insight on SOT101 for the Treatment of Advanced Metastatic Solid Tumors
VIEWPOINTS

PharmaShots Interview: SOTIO’ Richard Sachse Shares Insight on SOT101 for the Treatment of Advanced/Metastatic Solid Tumors

In an interview with PharmaShots, Richard Sachse, Chief Medical Officer & Managing Director at SOTIO shared his views on the data of SOT101 in the P-I/Ib (AURELIO-03) study for the treatment of advanced/metastatic solid tumors Shots: The P-I/Ib (AURELIO-03) study evaluates SOT101 as monothx. & in combination with pembrolizumab in patients with advanced/metastatic solid tumors The results showed that 13 patients…
April 6, 2022

Read more

Load more

Sign Up to Our Newsletter

Be the first to know the latest updates

[mc4wp_form id="13387" element_id="style-1"]